Skip to content

Protagenic Therapeutics, Inc.\new: 10-Q filed 2016-08-15

What Protagenic Therapeutics, Inc.\new reported in its quarterly report filed 2016-08-15 (fiscal Q2 2016): 23 published measures, 59 facts as tagged in accession 0001437749-16-037450.

This filing

Form
10-Q (quarterly report)
Filed
2016-08-15
Fiscal period
fiscal Q2 2016
Accession
0001437749-16-037450 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Protagenic Therapeutics, Inc.\new filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-06-303,789,628USD
At 2015-12-3111,142USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-06-303,186,531USD
At 2015-12-31-667,216USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-06-303,788,189USD
At 2015-12-313,343USD
At 2015-06-305,339USD
At 2014-12-3122,733USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-524,488USD91
2016-01-01 to 2016-06-30-1,264,273USD182
2015-04-01 to 2015-06-30-109,119USD91
2015-01-01 to 2015-06-30-146,910USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2016-01-01 to 2016-06-300USD182
2015-01-01 to 2015-06-300USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2016-01-01 to 2016-06-304,302,437USD182
2015-01-01 to 2015-06-3050,201USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-06-30-7,570,570USD
At 2015-12-31-6,306,297USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-06-30239,865USD182
2015-01-01 to 2015-06-3081,077USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-496,656USD91
2016-01-01 to 2016-06-30-1,222,398USD182
2015-04-01 to 2015-06-30-100,963USD91
2015-01-01 to 2015-06-30-150,884USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-06-303,788,189USD
At 2015-12-313,343USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-04-01 to 2016-06-301,767USD91
2016-01-01 to 2016-06-307,161USD182

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-06-30603,097USD
At 2015-12-31678,358USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-04-01 to 2016-06-30496,656USD91
2016-01-01 to 2016-06-301,222,398USD182
2015-04-01 to 2015-06-30100,963USD91
2015-01-01 to 2015-06-30150,884USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-04-01 to 2016-06-30374,206USD91
2016-01-01 to 2016-06-30422,721USD182
2015-04-01 to 2015-06-3039,975USD91
2015-01-01 to 2015-06-3061,424USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-06-3086,078shares
At 2015-12-316,612,838shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-06-3010,928,024USD
At 2015-12-316,612,838USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2016-06-30-170,943USD
At 2015-12-31-148,651USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2015-12-316,230USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-502,620USD91
2016-01-01 to 2016-06-30-1,241,981USD182
2015-04-01 to 2015-06-30-96,304USD91
2015-01-01 to 2015-06-30-147,019USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-30122,450USD91
2016-01-01 to 2016-06-30395,508USD182
2015-04-01 to 2015-06-3060,988USD91
2015-01-01 to 2015-06-3089,460USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2016-01-01 to 2016-06-30234USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-27,832USD91
2016-01-01 to 2016-06-30-41,875USD182
2015-04-01 to 2015-06-30-8,156USD91
2015-01-01 to 2015-06-303,974USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2015-01-01 to 2015-06-3050,201USD181

Inspect the source

Entity
Protagenic Therapeutics, Inc.\new / CIK 0001022899
Captured
2026-09-20T05:13:45.961Z
SEC response SHA-256
65b45c5addd26cd3e105dbeb1582537b1352dc73c447a8d926c77d81587fc033

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001022899.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))